Why Bioventus Inc.’s (BVS) Stock Is Up 5.22%
As of Tuesday, July 28, Bioventus Inc.’s BVS share price has surged by 5.22%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Commentary & Analysis
Why Bioventus Inc.’s (BVS) Stock Is Down 5.20%
As of Friday, July 10, Bioventus Inc.’s BVS share price has dipped by 5.20%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Bioventus Inc.’s (BVS) Stock Is Up 6.30%
As of Monday, July 06, Bioventus Inc.’s BVS share price has surged by 6.30%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Bioventus Inc.’s (BVS) Stock Is Up 12.60%
As of Monday, July 06, Bioventus Inc.’s BVS share price has surged by 12.60%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Bioventus Inc.’s (BVS) Stock Is Up 5.06%
As of Wednesday, June 03, Bioventus Inc.’s BVS share price has surged by 5.06%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | BVS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $892.9 | $334.8 | 44% |
|
| Shares Out (Mil) | 70.0 | 41.7 | 55% |
|
| Institutional Ownership | 92.3% | 77.3% | 61% |
|
| Float (Mil) | 33.3 | 34.7 | 39% |
|
| Beta | 0.67 | 0.86 | 39% |
|
| Avg Daily Volume (000s) | 650 | 266 | 63% |
|
| Price Change (52-week) |
101.5% | 60.7% | 92% |
|
| Growth | BVS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 12.1% | 11.8% | 65% |
|
| Net Income (5yr) | 6.7% | (5.8%) | 49% |
|
| EPS (5yr) | (37.1%) | 10.7% | 6 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (50.2%) | (16.1%) | 7% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 5 | |
| Current EPS | $0.218 | $0.780 | $0.908 | |
| Month Ago EPS | $0.216 | $0.776 | $0.906 | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | $0.235 | $0.750 | $0.870 | |
| Year/Year Chg | 445.0% | 136.4% | 226.4% | |
| Financials | BVS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $576 | $152 | 43% |
|
| Net Income (TTM) (Mil) | $29 | ($11) | 52% |
|
| EPS (TTM) | $0.425 | ($0.500) | 52% |
|
| Operating Cash Flow (TTM) (Mil) | $103 | ($2) | 53% |
|
| Net Cash Flow (TTM) (Mil) | $13 | $1 | 60% |
|
| Long-Term Debt (Q1) (Mil) | $266 | $22 | 53% |
|
| Enterprise Value (Q1) (Mil) | $887 | $304 | 40% |
|
| Valuation | BVS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.72 | 2.88 | 77% |
|
| P/E | 32.7 | 30.5 | 72% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.9 | na |
|
| Ratios | BVS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 68.7% | 59.1% | 80% |
|
| Net Margin | 4.9% | (7.7%) | 48% |
|
| ROA | 4.2% | (13.7%) | 68% |
|
| ROE | 16.9% | (15.9%) | 75% |
|
| Liabilities to Assets | 64.0% | 44.9% | 59% |
|
| F-Score | 8 | 4 | 94% |
|
Passing Stock Screens
As of 7/30/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Driehaus Screen
Factors: Size, Momentum, Growth, Earnings Estimates
Classic momentum approach that seeks out stocks that are rapidly rising in price with the belief that the rising price will attract other investors.
| Performance Since Inception: | 13.5% |
| +/- S&P 500: | +6.0 |
